Disclosures
PC reports research funding from AbbVie, Acerta, F. Hoffmann-LaRoche, Gilead, GlaxoSmithKline,
Janssen-Cilag and Novartis, honoraria for scientific talks from AbbVie, F. Hoffmann-LaRoche
and Janssen-Cilag and for advisory boards from AbbVie, Acerta, AstraZeneca, Janssen-Cilag
and Novartis, as well as travel grants from AbbVie, F. Hoffmann LaRoche, Gilead, Janssen-Cilag
and Mundipharma. JvT reports research funding from F. Hoffmann-LaRoche and Janssen-Cilag,
honoraria for advisory boards from AbbVie, F. Hoffmann-LaRoche and Janssen-Cilag,
as well as travel grants from Celgene, F. Hoffmann-LaRoche and Janssen-Cilag. JB reports
honoraria and travel grants from F. Hoffmann-LaRoche. PL reports research funding
from AbbVie, F. Hoffmann-LaRoche and Janssen-Cilag, honoraria from Janssen-Cilag and
travel grants from F. Hoffmann-LaRoche, Janssen-Cilag and Mundipharma. OA-S reports
personal fees from F. Hoffmann- LaRoche, AbbVie and Gilead. WH reports research funding
from MSD (Merck Sharp & Dohme) and Pfizer, honoraria for scientific talks from Alexion,
Basilea, Gilead, MSD (Merck Sharp & Dohme) and Pfizer, advisory boards from Gilead
Science, MSD, Pfizer, travel grants from Alexion, Astellas, Basilea, Gilead Science,
MSD and Pfizer (all outside the submitted work). UVK reports honoraria for advisory
boards from AbbVie, Amgen, F. Hoffmann-LaRoche, Gilead, Lilly and MSD. JD reports
honoraria for scientific talks from F. Hoffmann-LaRoche, Janssen-Cilag, Celgene; advisory
boards from AbbVie, Amgen, Bristol-Myers Squibb, Janssen-Cilag, Novartis, Gilead;
travel grants from Celgene, F. Hoffmann LaRoche, Gilead, Janssen-Cilag, and Mundipharma.
ET reports travel grants from Abbvie, Celgene and Gilead. MHe reports honoraria for
advisory boards from AbbVie and F. Hoffmann-LaRoche, and travel grants from AbbVie
and F. Hoffmann-LaRoche. AMF reports research grants from Celgene and travel grants
from AbbVie, F. Hoffmann-LaRoche and Mundipharma. KF reports travel grants from F.
Hoffmann- LaRoche. KAK reports research support and honoraria for consultancy or advisory
boards from AbbVie, F. Hoffmann-LaRoche and Mundipharma. SB reports grants and personal
fees from AbbVie, F-Hoffmann-LaRoche and Janssen, grants from Celgene and Genentech,
and personal fees from Becton Dickinson and Novartis. MR reports research funding
from AbbVie, Amgen, F. Hoffmann-LaRoche and Gilead. MK reports honoraria for consultancy
or advisory boards from AbbVie and F. Hoffmann-LaRoche. CMW reports research support,
honoraria for consultancy or advisory boards and travel support from AbbVie, F. Hoffmann-LaRoche,
Genentech, Gilead, GlaxoSmithKline, Janssen-Cilag, Mundipharma and Pharmacyclics.
SS reports research support, honoraria for consultancy or advisory boards and travel
support from AbbVie, Amgen, Celgene, F. Hoffmann-LaRoche, Genentech, Gilead, GlaxoSmithKline,
Janssen-Cilag, Mundipharma, Novartis and Pharmacyclics. BE reports research support
and honoraria for consultancy or advisory boards from AbbVie and F. Hoffmann- LaRoche.
MHa reports research support and honoraria from Roche, Gilead, Mundipharma, Janssen,
Celgene, Pharmacyclics and Abbvie. NP, SR and MF report no conflicts of interest.
Contributions
PC, JvT, JB, SB, BE and MH were responsible for the conception and design of the study;
PC, JvT, SR, JB, MF, PL, NP, OAS, AMF and KF were responsible for the trial management;
PC, JvT, MF, PL, NP, OA-S, WH, UV-K, JD, ET, MHe, SS, SB, MR, MK, CMW, SS, BE and
MH were responsible for the recruitment and treatment of patients; PC, JvT, SR, JB,
MF, PL and NP had access to the raw data; PC, MF, PL and NP performed a central review
of all clinical data; ET, KAK, SB, MR, MK and SS performed the laboratory analyses;
SR and JB performed the statistical analysis. All authors interpreted the data; PC
wrote the first draft of the manuscript and all authors approved the final manuscript.